Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
What the film says
Most childhood brain tumors start in the cerebellum, low at the back of the head, where balance and coordination live. That is where medulloblastoma begins, the most common malignant brain tumor of childhood.
Treatment is a hard road: surgery, radiation to the whole brain and spine, then months of chemotherapy. Many children are cured, but it is tough on a growing brain. And when the tumor comes back after all of that, there are very few options left. That is the problem this trial is trying to solve.
Here is the idea. What if the treatment were a virus?
Almost everyone has met herpes simplex virus type one, the cold-sore virus. It is naturally good at getting into nerve cells. Scientists rebuilt it so it can grow inside cancer cells, but not healthy brain. The rebuilt virus is called G207. The strategy: let it do what viruses do, only inside the tumor, and let the immune system notice.
How does it work? Two edits to the virus's genes.
The first edit takes away the virus's key. Every healthy cell has an alarm: when it senses a virus, an enzyme called PKR shuts down the cell's protein factory, and the infection stalls. Natural herpes carries a gene that switches that alarm off. Scientists deleted it. Now healthy cells stop G207. But many cancer cells disabled that alarm on their way to becoming cancer. Inside them, G207 multiplies.
The second edit takes away a tool. To copy itself, the virus needs an enzyme that builds DNA. Scientists broke the virus's own copy, so G207 must borrow it from the cell it is in, and only dividing cells have it. Tumor cells divide constantly. Most mature brain cells do not.
Together, the two edits mean the virus can only thrive in the tumor. It multiplies inside cancer cells until they burst, spreads to the cancer cells next door, and all that debris draws in the immune system.
That last part may matter most. In the first trial of G207 in children, biopsies before treatment showed almost no immune cells in the tumor, what doctors call a cold tumor. Months later, the same tumors were crowded with T cells. Twelve children were treated. No serious side effects were blamed on the virus, and median survival was twelve point two months, against a historical five point six. A small first study, not proof, published in the New England Journal of Medicine in twenty twenty-one.
One more piece. In the lab, a small dose of radiation makes tumor cells produce more of the very enzyme the virus lost, which helps it multiply. So most children in this trial get one low dose of radiation the day after the virus.
That first trial treated the upper brain. This one takes G207 to the cerebellum for the first time, after mouse studies showed it was safe there. Children and young adults from three to twenty-one whose cerebellar tumor has returned receive a single infusion of G207 through fine catheters placed in the tumor. The first question is safety; the second is dose. It is led by Gregory Friedman at M D Anderson, with sites in Houston, Birmingham, and St. Louis.
Everything in this film comes from the published record, and it is not medical advice.
Sources behind this film
Bernstock JD. Cancer Gene Ther, 2020
Most childhood brain tumors start in the cerebellum; it handles balance and coordination; Medulloblastoma is the most common malignant brain tumor of childhood; Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; "Many children are cured" (+3 more lines)
Bernstock JD. Hum Gene Ther, 2020
Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; Standard treatment is "harmful to the developing brain"; This trial: ages 3–21, recurrent/progressive cerebellar tumors, single infusion via intratumoral catheters, 3+3 design, four cohorts, first cohort virus alone, cohorts 2–4 add 5 Gy within 24 h, primary goal safety
Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; Two edits: "takes away the key" (γ34.5 deletion) and "takes away a tool" (ICP6/ribonucleotide reductase); HSV-1 is the cold-sore virus and naturally infects nerve cells; G207 is HSV-1 (strain F) engineered to replicate in tumor cells, not normal brain (+4 more lines)
Friedman GK. N Engl J Med, 2021
Twelve children treated (ages 7–18, recurrent/progressive high-grade glioma); First pediatric trial: 12 children, recurrent/progressive high-grade glioma, ages 7–18; no DLT or SAE attributed to G207; median OS 12.2 mo vs historical 5.6 mo; pre-treatment biopsies "cold", post-treatment tumors with many T cells; NEJM April 2021; That trial was supratentorial
G207 is HSV-1 (strain F) engineered to replicate in tumor cells, not normal brain; Edit 2: UL39/ICP6 (viral ribonucleotide reductase) inactivated by lacZ insertion; needed for viral DNA synthesis in non-dividing cells; dividing cells supply the cellular equivalent
Todo T. Front Biosci, 2008
Edit 1: both copies of γ34.5 deleted; γ34.5 counters the PKR shutdown of protein synthesis; tumor cells have low PKR activity so the deleted virus still replicates there
Wilcox DR. PLoS Pathog, 2016
Edit 1: both copies of γ34.5 deleted; γ34.5 counters the PKR shutdown of protein synthesis; tumor cells have low PKR activity so the deleted virus still replicates there
Kangas C. Viruses, 2021
"Many" not "all" cancer cells have low PKR — heterogeneity
Scanlan H. Front Oncol, 2022
Edit 2: UL39/ICP6 (viral ribonucleotide reductase) inactivated by lacZ insertion; needed for viral DNA synthesis in non-dividing cells; dividing cells supply the cellular equivalent
Markert JM. Mol Ther, 2014
Low-dose radiation upregulates cellular ribonucleotide reductase, the enzyme G207 lacks, enhancing replication
Stanziale SF. Surgery, 2002
Low-dose radiation upregulates cellular ribonucleotide reductase, the enzyme G207 lacks, enhancing replication
The drug
Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
Outcomes for children with recurrent or progressive cerebellar malignant brain tumors are very poor, and there are a lack of effective salvage therapies once a patient fails standard treatments. G207 is an oncolytic herpes simplex virus-1 (HSV) that has been successfully engineered to introduce mutations in the virus that enable it to selectively replicate in and kill cancer cells, but not normal cells.
Replication of G207 in the tumor not only kills the infected tumor cells, but causes the tumor cell to act as a factory to produce new virus. These virus particles are released as the tumor cell dies, and can then proceed to infect other tumor cells in the vicinity, and continue the process of tumor kill.
The study
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.